Pharmaceutical

Genentech wins FDA approval for second stroke treatment

Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

Mar 5, 2025 - 06:00
Genentech wins FDA approval for second stroke treatment
Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.
Read the original article

Tags:

Previous Article

Reflecting on a milestone year for cell and gene therapies

Next Article

EU set to approve AstraZeneca’s Imfinzi-chemo combo for NSCLC

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Agomab wins FDA orphan drug status for idiopathic pulmonary fibrosis asset

Agomab wins FDA orphan drug status for idiopathic pulmo...

Jun 8, 2024

Novo Nordisk and NanoVation sign $600m deal in rare and cardiometabolic diseases

Novo Nordisk and NanoVation sign $600m deal in rare and...

Sep 20, 2024

STAT+: Another powerful congressional committee is ready to take on PBMs

STAT+: Another powerful congressional committee is read...

Apr 27, 2023